Use of multikinase inhibitors/lenvatinib concomitant with antiresorptive therapy for bone metastases from radioiodine‐resistant differentiated thyroid cancer

Bone is the second most common distant metastasis site in differentiated thyroid cancer (DTC) and is normally associated with the presence of other metastases, which are usually radioiodine‐resistant. The presence of bone metastasis (BM) determines low survival and greater morbidity due to the frequ...

Descripción completa

Detalles Bibliográficos
Autor principal: Navarro‐Gonzalez, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9537057/
https://www.ncbi.nlm.nih.gov/pubmed/35785524
http://dx.doi.org/10.1002/cam4.4983

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9537057/
https://www.ncbi.nlm.nih.gov/pubmed/35785524
http://dx.doi.org/10.1002/cam4.4983

Ejemplares similares